ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financi...(6966 Research and development ...),Health

Research and development 10,543 7,529 23,365 14,834

Marketing, general and

administrative 9,027 7,047 24,341 18,711

Intangible amortization and

acquisition of technology rights 1,401 1,341 4,719 4,327

-------- ------- -------- --------

Total costs and expenses 23,000 20,785 59,325 54,838

-------- ------- -------- --------

Operating income 27,944 34,461 96,749 73,748

Net (loss) on bond redemption - - - (1,127)

Interest income 6,978 2,512 17,046 6,669

Interest expense (1,435) 179 (2,961) (686)

-------- ------- -------- --------

Income before income tax expense 33,487 37,152 110,834 78,604

Income tax expense 12,199 13,874 35,852 29,935

-------- ------- -------- --------

Net income $21,288 $23,278 $74,982 $48,669

======== ======= ======== ========

Basic net income per share $0.30 $0.34 $1.07 $0.71

======== ======= ======== ========

Diluted net income per share $0.26 $0.33 $0.96 $0.69

======== ======= ======== ========

Shares used in computing net

income per share amounts

Basic 69,835 69,119 69,807 68,756

======== ======= ======== ========

Diluted 83,901 70,292 79,747 70,151

'/>"/>